Economics in getting a compound approved and commercialized are evolving. Drug companies have reduced budgets that historically funded vast R&D teams. Innovators are chasing tight investment dollars. The two camps are increasingly collaborating.
There is a self-selection factor rewarding start-ups. Specifically, they can’t attract funding or licensing deals unless they’ve protected their intellectual property, showed
Over the last few months I have had the chance to speak to entrepreneurs from Brazil, China, Estonia, France, Germany, Guatemala, Israel, Norway, Singapore and Ukraine seeking to operate and solicit investment here in the U.S. As an attorney, I’m expected to focus on best legal practices. They’re indeed important, but perhaps not worth quite so much energy if the company isn’t on a course to succeed as a business.
An important part of any angel or venture financing is the pro forma capitalization table (referred to as the “Cap Table”). On Wednesday, Sept. 14 from 12:00 pm -1:00pm EDT, Greenberg Traurig shareholder